Pliant Therapeutics Inc(PLRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 5:48 PM ET (Korea 10/29 06:48)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.5 | Insider Own | 2.64% | Shs Outstand | 61.9M | Perf Week | 0.45% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 5.16% | Insider Trans | - | Shs Float | 60.3M | Perf Month | -17.61% |
| Enterprise Value | -0.07B | PEG | - | EPS next Q | -0.37 | Inst Own | 77.35% | Short Float | 7.69% | Perf Quarter | -16.06% |
| Income | -0.09B | P/S | - | EPS this Y | 41.07% | Inst Trans | -7.51% | Short Ratio | 11.58 | Perf Half Y | -26.46% |
| Sales | 0.00B | P/B | 0.37 | EPS next 5Y | 23.86% | ROA | -37.69% | Short Interest | 4.63M | Perf YTD | -27.07% |
| Book/sh | 2.37 | P/C | 0.35 | EPS past 3/5Y | 6.05% -15.81% | ROE | -50.29% | 52W High | -51.38% ($1.83) | Perf Year | -50.01% |
| Cash/sh | 2.55 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.22% | 52W Low | 7.17% ($0.83) | Perf 3Y | -93.36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 55.84% | Gross Margin | - | Volatility(W/M) | 6.13% 5.49% | Perf 5Y | -94.6% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.9 | EPS Q/Q | 48.78% | Profit Margin | - | RSI (14) | 38.76 | Recom | 3.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.9 | Sales Q/Q | - | SMA20 | -5.78% ($0.94) | Beta | 1.34 | Target Price | $1.51 |
| Payout | - | Debt/Eq | 0.2 | Earnings | 2026/8/11 | SMA50 | -15.65% ($1.06) | Rel Volume | 0.3 | Prev Close | $0.86 |
| Employees | 49 | LT Debt/Eq | 0.18 | EPS/Sales Surpr. | -5.32% - | SMA200 | -23.68% ($1.17) | Avg Volume(3M) | 0.40M | Price | $0.89 |
| IPO | 2020/6/3 | Option/Short | Yes/Yes | Trades | 359 | Volume | 118,083 | Change | 3.82% |
🧬 This is a U.S. biotech company developing therapeutics for fibrotic diseases and cancer based on integrin biology, which regulates cell adhesion and signaling. The company is currently facing a major setback with the recent clinical hold on its lead pipeline candidate, but it is pursuing a strategic pivot into oncology and muscle spasticity based on its advanced technology platform.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
PLRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +41.1% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 77.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #409 of 594 in the industry
Based on market cap of $55M.
ONCY#406 Oncolytics Biotech Inc $56M PER - 
HYFT#407 MindWalk Holdings Corp $56M PER - 
INKT#408 MiNK Therapeutics Inc $55M PER - PLRX#409 Pliant Therapeutics Inc $55M PER - 
ALPS#410 ALPS Group Inc $54M PER - 
FAQ
What kind of company is PLRX?
PLRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLRX?
The market cap of PLRX is approximately $55M, ranking 4,808 within its sector.
What is the 52-week high and low for PLRX?
PLRX has recorded a 52-week high of $1.83 and a low of $0.83.
